JP2022516883A5 - - Google Patents

Info

Publication number
JP2022516883A5
JP2022516883A5 JP2021538127A JP2021538127A JP2022516883A5 JP 2022516883 A5 JP2022516883 A5 JP 2022516883A5 JP 2021538127 A JP2021538127 A JP 2021538127A JP 2021538127 A JP2021538127 A JP 2021538127A JP 2022516883 A5 JP2022516883 A5 JP 2022516883A5
Authority
JP
Japan
Prior art keywords
cancer
alkyl
optionally substituted
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021538127A
Other languages
English (en)
Japanese (ja)
Other versions
JP7418441B2 (ja
JP2022516883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068652 external-priority patent/WO2020139991A1/en
Publication of JP2022516883A publication Critical patent/JP2022516883A/ja
Publication of JP2022516883A5 publication Critical patent/JP2022516883A5/ja
Priority to JP2023208546A priority Critical patent/JP2024015340A/ja
Application granted granted Critical
Publication of JP7418441B2 publication Critical patent/JP7418441B2/ja
Priority to JP2025113748A priority patent/JP2025133887A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021538127A 2018-12-27 2019-12-27 Mat2Aのアザ複素二環式阻害剤、およびがんの治療のための使用方法 Active JP7418441B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023208546A JP2024015340A (ja) 2018-12-27 2023-12-11 Mat2Aのアザ複素二環式阻害剤、およびがんの治療のための使用方法
JP2025113748A JP2025133887A (ja) 2018-12-27 2025-07-04 Mat2aのアザ複素二環式阻害剤、およびがんの治療のための使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785519P 2018-12-27 2018-12-27
US62/785,519 2018-12-27
PCT/US2019/068652 WO2020139991A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023208546A Division JP2024015340A (ja) 2018-12-27 2023-12-11 Mat2Aのアザ複素二環式阻害剤、およびがんの治療のための使用方法

Publications (3)

Publication Number Publication Date
JP2022516883A JP2022516883A (ja) 2022-03-03
JP2022516883A5 true JP2022516883A5 (enExample) 2022-11-08
JP7418441B2 JP7418441B2 (ja) 2024-01-19

Family

ID=69400625

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021538127A Active JP7418441B2 (ja) 2018-12-27 2019-12-27 Mat2Aのアザ複素二環式阻害剤、およびがんの治療のための使用方法
JP2023208546A Pending JP2024015340A (ja) 2018-12-27 2023-12-11 Mat2Aのアザ複素二環式阻害剤、およびがんの治療のための使用方法
JP2025113748A Pending JP2025133887A (ja) 2018-12-27 2025-07-04 Mat2aのアザ複素二環式阻害剤、およびがんの治療のための使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023208546A Pending JP2024015340A (ja) 2018-12-27 2023-12-11 Mat2Aのアザ複素二環式阻害剤、およびがんの治療のための使用方法
JP2025113748A Pending JP2025133887A (ja) 2018-12-27 2025-07-04 Mat2aのアザ複素二環式阻害剤、およびがんの治療のための使用方法

Country Status (38)

Country Link
US (2) US12077534B2 (enExample)
EP (1) EP3902803B1 (enExample)
JP (3) JP7418441B2 (enExample)
KR (2) KR102823567B1 (enExample)
CN (1) CN113454085B (enExample)
AR (1) AR117544A1 (enExample)
AU (1) AU2019416349B2 (enExample)
CA (1) CA3124952C (enExample)
CL (1) CL2021001721A1 (enExample)
CO (1) CO2021009879A2 (enExample)
CR (1) CR20210410A (enExample)
DK (1) DK3902803T3 (enExample)
EA (1) EA202191801A1 (enExample)
ES (1) ES2942310T3 (enExample)
FI (1) FI3902803T3 (enExample)
GE (2) GEP20237519B (enExample)
HR (1) HRP20230161T1 (enExample)
HU (1) HUE061834T2 (enExample)
IL (1) IL284326B2 (enExample)
JO (1) JOP20210172B1 (enExample)
LT (1) LT3902803T (enExample)
MA (1) MA54608B1 (enExample)
MD (1) MD3902803T2 (enExample)
MX (1) MX2021007829A (enExample)
MY (1) MY206578A (enExample)
PE (1) PE20212090A1 (enExample)
PH (1) PH12021551490A1 (enExample)
PL (1) PL3902803T3 (enExample)
PT (1) PT3902803T (enExample)
RS (1) RS64135B1 (enExample)
SA (1) SA521422405B1 (enExample)
SG (1) SG11202106637SA (enExample)
SI (1) SI3902803T1 (enExample)
SM (1) SMT202300109T1 (enExample)
TW (1) TWI816962B (enExample)
UA (1) UA127525C2 (enExample)
WO (1) WO2020139991A1 (enExample)
ZA (1) ZA202104423B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
US20240124454A1 (en) * 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
DE102021102487A1 (de) * 2021-02-03 2022-08-04 Aixinno Limited Verfahren zum Handhaben biologischer Zellkulturen
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
KR20240148320A (ko) * 2021-12-17 2024-10-11 탱고 테라퓨틱스, 인크. N-(6-아미노-5-메틸피리딘-3-일)-2-(벤조[d]티아졸-5-일)-5-메틸피페리딘-1-일)-2-옥소아세트아마이드의결정질 형태, 약제학적 조성물 및 이의 사용 방법
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023169554A1 (zh) * 2022-03-11 2023-09-14 赛诺哈勃药业(成都)有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
JP2025521737A (ja) 2022-06-27 2025-07-10 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼(石家庄)有限公司 三環式化合物およびその使用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AU2023361063A1 (en) 2022-10-13 2025-04-17 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
CN121241050A (zh) * 2023-03-06 2025-12-30 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
CN121586715A (zh) * 2023-06-14 2026-02-27 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
CA2420286A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP6832430B2 (ja) * 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ, インコーポレイテッド 細胞代謝過程の阻害剤
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
US11524960B2 (en) 2018-03-30 2022-12-13 Servier Pharmaceuticals Llc Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
EA202191800A1 (ru) * 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
SG11202112952SA (en) * 2019-05-31 2021-12-30 Servier Lab Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Similar Documents

Publication Publication Date Title
JP2022516883A5 (enExample)
JP2021519783A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
KR102166002B1 (ko) 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
JP2024516997A5 (enExample)
JP2024520481A (ja) チェックポイントキナーゼ1(chk1)阻害剤およびその使用
HRP20230161T1 (hr) Aza-heterobiciklički inhibitori za mat2a i postupci uporabe za liječenje raka
RU2014118677A (ru) Ингибиторы киназ типа polo
WO2024118564A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
JP2017128612A (ja) Arry−380の多形体、選択的erbb2(her2)阻害剤、およびそれらを含有する薬学的組成物
JP2011511095A5 (enExample)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2020505356A5 (enExample)
JP2020504716A5 (enExample)
TW202214630A (zh) 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN110240587A (zh) 一类芳基二氟苄基醚类化合物、制备方法及用途
JP2015524825A5 (enExample)
JPS61167682A (ja) 抗精神病薬,2‐(4‐ブチルピペラジン‐1‐イル)ピリジン類の環状イミド誘導体
TW385312B (en) Novel cephalosporin cyclic allyl derivatives
CA3130471A1 (en) Pan-raf kinase inhibitor and use thereof
WO2024118596A1 (en) Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
RU2021121996A (ru) Аза-гетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак